Opinion

Video

Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies

Author(s):

Hope Rugo, MD,Aditya Bardia, MD, MPH

Experts on breast cancer discuss the potential adverse events related to trastuzumab deruxtecan (T-DXd).

Video content above is prompted by the following:

  • Can you describe the cardiotoxicity risk with T-DXd and the mechanism behind cardiovascular toxicity?
  • Please comment on your monitoring strategy for cardiotoxicity with T-DXd.
  • What patient symptoms do you monitor for? What are your left ventricular ejection fraction cutoffs to initiate, hold/delay, and discontinue therapy?
Related Videos
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center
Aditya Bardia, MD, MPH, FASCO, professor, Department of Medicine, Division of Hematology/Oncology, director, Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
Vered Stearns, MD
Kevin Kalinsky, MD, MS
Related Content
Breast Cancer | Image Credit: © Axel Kock – stock.adobe.com
December 12th 2024

Palbociclib Plus Anti-HER2 and Endocrine Therapy Prolongs PFS in HR+/HER2+ Breast Cancer

Jennie W. Taylor, MD, MPH, associate professor, clinical neurology, University of California, San Francisco, community engagement liaison, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
October 10th 2024

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer
December 12th 2024

Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Breast cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
December 11th 2024

Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer

Neoadjuvant Patritumab Deruxtecan ± Letrozole Shows Efficacy in High-Risk HR+/HER2– Breast Cancer
December 11th 2024

Neoadjuvant Patritumab Deruxtecan ± Letrozole Shows Efficacy in High-Risk HR+/HER2– Breast Cancer